Trial Profile
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PROSPECT
- Sponsors Bavarian Nordic; BN ImmunoTherapeutics
- 06 Apr 2022 This trial has been completed in Netherland (End Date: 02 Oct 2017), according to European Clinical Trials Database record.
- 28 Feb 2019 Argentina,Austria, Brazil, Chile, Czech Republic,Lithuania, Mexico, Panama, Slovakia, Switzerland, were the planned locations as per European Clinical Trials Database record.
- 28 Feb 2019 Results assessing median overall survival metastatic castration-resistant prostate cancer patients published in the Journal of Clinical Oncology.